OKYO Pharma (OKYO) Competitors $1.65 -0.20 (-10.81%) Closing price 03:59 PM EasternExtended Trading$1.68 +0.03 (+1.82%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. IVA, CRDF, VYGR, ELDN, TLSA, INMB, NBTX, INBX, PRME, and OGIShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include Inventiva (IVA), Cardiff Oncology (CRDF), Voyager Therapeutics (VYGR), Eledon Pharmaceuticals (ELDN), Tiziana Life Sciences (TLSA), INmune Bio (INMB), Nanobiotix (NBTX), Inhibrx (INBX), Prime Medicine (PRME), and Organigram (OGI). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Inventiva Cardiff Oncology Voyager Therapeutics Eledon Pharmaceuticals Tiziana Life Sciences INmune Bio Nanobiotix Inhibrx Prime Medicine Organigram OKYO Pharma (NASDAQ:OKYO) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Do institutionals and insiders hold more shares of OKYO or IVA? 3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community favor OKYO or IVA? Inventiva received 13 more outperform votes than OKYO Pharma when rated by MarketBeat users. However, 100.00% of users gave OKYO Pharma an outperform vote while only 82.76% of users gave Inventiva an outperform vote. CompanyUnderperformOutperformOKYO PharmaOutperform Votes11100.00% Underperform VotesNo VotesInventivaOutperform Votes2482.76% Underperform Votes517.24% Do analysts prefer OKYO or IVA? OKYO Pharma presently has a consensus price target of $7.00, suggesting a potential upside of 324.24%. Inventiva has a consensus price target of $10.40, suggesting a potential upside of 222.98%. Given OKYO Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe OKYO Pharma is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has preferable earnings and valuation, OKYO or IVA? OKYO Pharma has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/AInventiva$9.20M18.37-$119.51MN/AN/A Does the media prefer OKYO or IVA? In the previous week, OKYO Pharma had 3 more articles in the media than Inventiva. MarketBeat recorded 3 mentions for OKYO Pharma and 0 mentions for Inventiva. Inventiva's average media sentiment score of 0.00 beat OKYO Pharma's score of -0.35 indicating that Inventiva is being referred to more favorably in the news media. Company Overall Sentiment OKYO Pharma Neutral Inventiva Neutral Is OKYO or IVA more profitable? Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Inventiva N/A N/A N/A Which has more risk & volatility, OKYO or IVA? OKYO Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. SummaryOKYO Pharma and Inventiva tied by winning 6 of the 12 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.83M$2.92B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E RatioN/A30.5026.5819.71Price / SalesN/A400.42391.69116.98Price / CashN/A168.6838.2534.62Price / Book-8.253.286.794.50Net Income-$16.83M-$72.17M$3.23B$248.18M7 Day Performance23.13%4.26%4.03%1.14%1 Month Performance41.03%7.60%12.50%15.19%1 Year Performance12.24%-28.16%16.73%6.55% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma1.7534 of 5 stars$1.65-10.8%$7.00+324.2%+24.2%$55.83MN/A0.007IVAInventiva1.5119 of 5 stars$3.61-0.4%$10.40+188.5%-17.1%$189.18M$9.20M0.00100Gap DownCRDFCardiff Oncology1.5769 of 5 stars$2.75-0.2%$12.00+337.2%-13.3%$182.61M$683,000.00-2.9220News CoverageGap UpVYGRVoyager Therapeutics4.6852 of 5 stars$3.30-1.6%$13.97+323.9%-59.8%$181.12M$66.96M4.61100Gap UpELDNEledon Pharmaceuticals2.1648 of 5 stars$3.00+4.5%$12.50+316.7%-1.9%$177.55MN/A-1.4810Trending NewsEarnings ReportAnalyst RevisionGap UpTLSATiziana Life Sciences1.081 of 5 stars$1.52+1.3%N/A+94.8%$177.03MN/A0.008Gap UpINMBINmune Bio1.9905 of 5 stars$7.77+1.6%$22.80+193.6%-31.6%$175.23M$14,000.00-3.5010Gap UpNBTXNanobiotix1.7093 of 5 stars$3.71+11.3%$8.00+115.9%-46.1%$174.86M$-11,609,000.000.00100News CoverageGap UpINBXInhibrx1.9107 of 5 stars$11.87+1.4%N/A-62.1%$171.83M$200,000.000.00166Earnings ReportPRMEPrime Medicine3.7245 of 5 stars$1.32-1.9%$12.83+875.9%-84.4%$171.82M$3.85M-0.64234Trending NewsAnalyst ForecastAnalyst RevisionGap DownOGIOrganigram0.2595 of 5 stars$1.28-0.4%N/A-32.2%$170.64M$166.12M-3.36860 Related Companies and Tools Related Companies IVA Alternatives CRDF Alternatives VYGR Alternatives ELDN Alternatives TLSA Alternatives INMB Alternatives NBTX Alternatives INBX Alternatives PRME Alternatives OGI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OKYO Stock Free OKYO Stock Alerts